Gelişmiş Arama

Basit öğe kaydını göster

dc.contributor.authorAyçiçek Doğan, Berçem
dc.contributor.authorBerker, Dilek
dc.contributor.authorArduç, Ayşe
dc.contributor.authorTuna, Mazhar Müslüm
dc.contributor.authorİmga Nasıroğlu, Narin
dc.contributor.authorKarakılıç, Ersen
dc.contributor.authorNavdar Başaran, Mehtap
dc.contributor.authorIşık, Serhat
dc.contributor.authorAteş Tütüncü, Yasemin
dc.contributor.authorÜnal, Mustafa
dc.contributor.authorGüler, Serdar
dc.date.accessioned2019-05-13T08:57:29Z
dc.date.available2019-05-13T08:57:29Z
dc.date.issued2016
dc.identifier.citationAyçiçek Doğan, B., Berker, D., Arduç, A., Tuna, M. M., İmga Nasıroğlu, N., Karakılıç, E., Navdar Başaran, M., Işık, S. [et.al.]. (2016). Insulin resistance and androgen levels in eugonadic and hypogonadic women with prolactinoma. Minerva Endocrinologica, 41(2), 175-182.en_US
dc.identifier.issn0391-1977
dc.identifier.urihttps://hdl.handle.net/11491/941
dc.description.abstractBACKGROUND: Hyperprolactinemia is the most common endocrinologic disorder in causing menstrual irregularities. Although the correlation between hyperprolactinemia and menstrual dysfunction is widely known, the etiology of menstrual cycle disorders is not profoundly understood in patients with prolactinoma. We aimed to investigate the correlation between prolactin levels and insulin resistance and hyperandrogenism in patients with prolactinoma. METHODS: Sixty-four patients with microprolactinoma and 33 healthy women were enrolled. Thirty-six of these patients with prolactinoma (group 1) had an estradiol (E2) level under 30 pg/mL, and 28 (group 2) had an E2 level greater than 30 pg/mL. Blood samples were drawn to measure the levels of the following hormones: Follicle stimulating hormone (FSH), luteinizing hormone (LH), E2, prolactin (PRL), total testosterone (TT), androstenedione (AS) and dehydroepiandrostenedione sulphate (DHEAS). Body Mass Index (BMI of ?30 kg/m2) was excluded from the study. Insulin resistance (IR) was calculated by the HOMA-IR. RESULTS: BMI was higher in patients with prolactinoma than the control group (P=0.02, P=0.025, respectively). IR and glucose intolerance existence were higher in patients with prolactinoma (P=0.007, P=0.097, respectively) than the healthy women, but these differences did not exist between eugonadic and hypogonadic women with prolactinoma (P=0.020, P=0.032, respectively, Bonferroni correction). TT and AS were higher in eugonadic women with prolactinoma than the control group (P=0.004, P=0.003, Bonferroni correction, respectively). CONCLUSIONS: Our study revealed that the relationship between hyperprolactinemia and IR/glucose intolerance is irrespective of gonadal status in women with prolactinoma. Also, the study concluded that hyperandrogenism may be a cause of menstrual dysfunction in eugonadic women with prolactinoma. © 2014 EDIZIONI MINERVA MEDICA.en_US
dc.language.isoeng
dc.publisherEdizioni Minerva Medicaen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAndrogensen_US
dc.subjectInsulin Resistanceen_US
dc.subjectProlactinomaen_US
dc.titleInsulin resistance and androgen levels in eugonadic and hypogonadic women with prolactinomaen_US
dc.typeconferenceObjecten_US
dc.relation.journalMinerva Endocrinologicaen_US
dc.departmentHitit Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.identifier.volume41en_US
dc.identifier.issue2en_US
dc.identifier.startpage175en_US
dc.identifier.endpage182en_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster